| Host: |
HEK293 |
| Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-SARS COV2 Spike protein S Trimer-protein was developed from hek293. For use in research applications. |
| Conjugation: |
Unconjugated |
| Formulation: |
Lyophilised from 0.2 µm filtered PBS pH7.4. |
| Dilution Range: |
Spin the vial and reconstite in distilled water to a concentration not less than 0.1 mg/mL. This can then be diluted into other buffers. |
| Storage Instruction: |
The lyophilized protein is stable for at least 1 year from date of receipt at-20°C. NA |
| Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
| Immunoreactivity: |
The activity was tested by binding Human ACE2 in functional ELISA assay (see figure below). NA |
| Immunogen Region: |
ECD |
| Immunogen: |
DNA sequence encoding the COVID-19 Spike S protein extracellular domain, [16-1188]R683A (accession # QHD43416.1) fused to a a T4 Folsom trimerzation domain and a C-terminal His AVI tag was expressed in HEK Cells. NA |
| Background | Recombinant 2019-nCoV Spike S trimer protein is a protein consisting of the S1+S2 subunits amino acid residues. The protein has a theoretical MW of 140kDa, however due to glycosylation migrates as an approximately 200 kDa protein on reduced SDS-PAGE. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
